Purchase this article with an account.
A. R. MacDonald, P. Cheevers, A. Samad; Intravitreal Bevacizumab for the Treatment of Macular Edema Resulting From Idiopathic Parafoveal Telangectasia. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2720.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the safety and efficacy of intravitreal bevacizumab (AvastinÂ®, Genentech) in the treatment of macular edema resulting from idiopathic parafoveal telangectasia (IPT).
A retrospective study involving 6 eyes of 6 patients, 4 females and 2 males, with a mean age of 70.8 years (range: 56-86), with macular edema secondary to IPT. No previous treatment had been administered to these patients including laser therapy or intravitreal triamcinolone acetonide. Patients underwent three intravitreal injections of Bevacizumab 1.25mg at 6 week intervals. Baseline assessment included best corrected visual acuity (BCVA), intravenous fluorescein angiography (IVF), foveal thickness and macular volume as determined by optical coherence tomography (OCT). These parameters were reassessed at 18 weeks.
Mean BCVA was 0.37 +/-.13 LogMAR (range: 0.2 â€" 0.54) at baseline and increased to .30 +/- .19 LogMAR (range: 0 - 0.5) at 18 weeks (p = 0.15). Mean foveal thickness was 231.6 +/- 65.7u at baseline and decreased to 219.7 +/- 47.7u at 18 weeks. (p = 0. 21) Mean total macular volume decreased from 6.88+/- 0.55 mm3 at baseline to 6.72 +/- 0.39 mm3 at 18 weeks. (p = 0.05) No adverse events were observed, including inflammation, endophthalmitis, elevated intraocular pressure, retinal detachments or thromboembolic phenomenon. Microvascular leakage as determined by IVF was reduced from baseline in all patients.
This PDF is available to Subscribers Only